Locally advanced non-small cell lung cancer (NSCLC) is a highly heterogeneous disease. For patients with driver gene-negative, unresectable NSCLC, traditional treatment primarily involves concurrent chemoradiotherapy. With the advent of the immunotherapy era, integrated treatment strategies combining concurrent chemoradiotherapy with immunotherapy have significantly improved therapeutic outcomes and substantially extended survival periods. This article summarizes the interaction mechanisms and clinical research progress of radiotherapy, chemotherapy, and immune checkpoint inhibitors in the treatment of NSCLC. This review also provides perspectives on the development of therapies in the future and predictive biomarkers, serving as a reference for treatment options for patients with unresectable locally advanced NSCLC.

Brain metastases are the most common intracranial tumors, and their incidence is increasing with the improvement of systemic treatments and survival rates. Optimal treatment usually requires a multidisciplinary approach, including radiotherapy, surgical resection, chemotherapy, targeted therapy, and immunotherapy. Stereotactic radiotherapy, compared to whole-brain radiotherapy, offers improved local control rates and reduced risk of neurocognitive impairment, and has become a new standard option for the treatment of brain metastases. Additionally, the widespread use of targeted and immune therapies in brain metastases has significantly improved the survival of some patients. This article reviews and integrates recent literature on the treatment of brain metastases and analyzes the role of stereotactic radiotherapy in comprehensive treatment, aiming to provide a reference for the selection of clinical treatment plans.

At present, liver transplantation is the most effective method for the treatment of various end-stage liver diseases, and electronic health technology is a new medical service model, which can be used as an efficient and cost-effective alternative to the health management of liver transplant recipients. This paper summarizes the application of electronic health technology in postoperative health management of liver transplant recipients, including applications, robots, video conferencing, tablet computers, text messages, telephones and wearable devices, etc., summarizes the implementation effect of electronic health technology in health management of liver transplant recipients, and analyzes the limitations of research and application at the present stage. In order to provide basis and reference for Chinese medical staff to carry out electronic health technology in the health management of liver transplant recipients.

The symptom clusters increase the symptom distress of liver transplant recipients, reduces their treatment and nursing compliance, and greatly affects the prognosis quality of life of liver transplant recipients. This article reviews the concept, research status, assessment tools, influencing factors, and interventions for symptom clusters in liver transplant recipients, aiming to help clinical nurses formulate targeted interventions based on symptom clusters, provide effective symptom management for liver transplant recipients, reduce the physical and psychological damage caused by symptom clusters, and continuously improve the quality of life of liver transplant recipients.

The cross-lagged model is a longitudinal data analysis method that can analyze the mutual influence and causal relationships among variables in longitudinal studies. This article introduces an overview of the cross-lagged model and the application progress of the cross-lagged model in the field of nursing, including psychological nursing, community nursing, geriatric nursing, perinatal nursing, nursing management, and nursing education. It is expected to provide a reference for Chinese medical staff to apply the cross-lagged model in nursing practice.

The cross-lagged model is a longitudinal data analysis method that can analyze the mutual influence and causal relationships among variables in longitudinal studies. This article introduces an overview of the cross-lagged model and the application progress of the cross-lagged model in the field of nursing, including psychological nursing, community nursing, geriatric nursing, perinatal nursing, nursing management, and nursing education. It is expected to provide a reference for Chinese medical staff to apply the cross-lagged model in nursing practice.

At present, liver transplantation is the most effective method for the treatment of various end-stage liver diseases, and electronic health technology is a new medical service model, which can be used as an efficient and cost-effective alternative to the health management of liver transplant recipients. This paper summarizes the application of electronic health technology in postoperative health management of liver transplant recipients, including applications, robots, video conferencing, tablet computers, text messages, telephones and wearable devices, etc., summarizes the implementation effect of electronic health technology in health management of liver transplant recipients, and analyzes the limitations of research and application at the present stage. In order to provide basis and reference for Chinese medical staff to carry out electronic health technology in the health management of liver transplant recipients.

The symptom clusters increase the symptom distress of liver transplant recipients, reduces their treatment and nursing compliance, and greatly affects the prognosis quality of life of liver transplant recipients. This article reviews the concept, research status, assessment tools, influencing factors, and interventions for symptom clusters in liver transplant recipients, aiming to help clinical nurses formulate targeted interventions based on symptom clusters, provide effective symptom management for liver transplant recipients, reduce the physical and psychological damage caused by symptom clusters, and continuously improve the quality of life of liver transplant recipients.

Diabetes mellitus(DM)is an endocrine metabolic disease mainly characterized by chronic hyperglycemia,which seriously threatens the health and quality of life of human beings,and with the improvement of living standard and unhealthy lifestyle in China,the incidence of DM continues to rise and tends to be younger,so it is urgent to carry out in-depth research on hypoglycemic treatment.DM is pathologically based on absolute or relative insulin deficiency,and there is no radical cure for it,and Western medicine mostly adopts insulin injection or oral hypoglycemic drugs for symptomatic treatment,which is effective but prone to toxic side effects in long-term use.Chinese medicine has the advantages of multi-path and multi-target in treating DM,and plays a role in lowering blood sugar by promoting insulin secretion,improving insulin resistance,regulating glucolipid metabolism and anti-oxidative stress,etc.Its efficacy is remarkable and the rate of toxic side effects is low.In recent years,there have been more studies on the mechanism of action of traditional Chinese medicine and compound prescriptions on animal models of DM.By reviewing the relevant literature in recent years,the author has systematically sorted out the mechanism of hypoglycemic action of single Chinese medicine,traditional Chinese medicine compound prescriptions,effective components of traditional Chinese medicine and their related experimental designs,from promoting insulin secretion,inhibiting gluconeogenesis,promoting glycogen synthesis,improving insulin resistance,inhibiting glycosidase activity,alleviating oxidative stress damage,inhibiting inflammatory response and regulating intestinal stress.The study and experimental design of the hypoglycemic mechanism of Chinese medicine were summarized in terms of promoting insulin secretion,inhibiting gluconeogenesis,promoting glycogen synthesis,improving insulin resistance,inhibiting glucosidase activity,alleviating oxidative stress damage,inhibiting inflammatory response and regulating intestinal flora,etc.,with a view to providing reference for the wider clinical application of Chinese medicine in hypoglycemia and its in-depth pharmacodynamic study.

ObjectiveTo evaluate the efficacy and safety of various oral Chinese patent medicines in the adjuvant treatment of chronic prostatitis/chronic pelvic pain syndrome （CP/CPPS） based on network Meta-analysis. MethodRandomized controlled trials （RCTs） of oral Chinese patent medicine in the adjuvant treatment of CP/CPPS were retrieved from the databases of China National Knowledge Infrastructure （CNKI）， Wanfang， VIP， SinoMed， PubMed， Cochrane Library， EMbase， and Web of Science from database inception to November， 2022. The quality of the included literature was evaluated according to the Cochrane risk-of-bias tool， and the data were analyzed by RevMan 5.4 and Stata 16 software. ResultA total of 63 RCTs were included， with 13 kinds of oral Chinese patent medicines involved， including Qianlie Shutong capsules， Ningmitai capsules， Qianlie Beixi capsules， Sanjin tablets， etc. The results of the network Meta-analysis showed that in terms of clinical effective rate， the intervention measure ranked first was Qianlie Beixi capsules combined with conventional western medicine. In terms of reducing pain， the intervention measure ranked first was Sanjin tablets combined with conventional western medicine. In terms of reducing urination disorder， the intervention measure ranked first was Relinqing granules combined with conventional western medicine. In terms of improving quality of life， the intervention measure ranked first was Qianlie Beixi capsules combined with conventional western medicine. In terms of reducing the total National Institutes of Health Chronic Prostatitis Symptom Index （NIH-CPSI） score， the intervention measure ranked first was Yinhua Miyanling tablets combined with conventional western medicine. In terms of reducing leukocyte count in prostatic secretions， the intervention measure ranked first was Qianlie Jiedu capsules combined with conventional western medicine. In terms of safety， the intervention measure with the least adverse reactions was Qianlie Shutong capsules combined with conventional western medicine. The cluster analysis results showed that Qianlie Shutong capsules combined with conventional western medicine had outstanding efficacy and high safety. ConclusionOral Chinese patent medicine in the adjuvant treatment of CP/CPPS can improve the comprehensive efficacy， reduce the NIH-CPSI score and leukocyte count in prostatic secretions， and improve the quality of life of patients. For clinical treatment， the preferred choice is Qianlie Beixi capsules or Qianlie Shutong capsules combined with conventional western medicine. Limited by the quantity and quality of literature included in this study， the results need to be verified by high-quality studies with a larger sample size.